Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Main Article Content

Jerry Bagel
April Armstrong
Richard Warren
Kim Papp
Diamant Thaçi
Alan Menter
Jennifer Cather
Matthias Augustin
Lauren Hippeli
Carolin Daamen
Christopher Griffiths

Keywords

deucravacitinib, plaque psoriasis, tyrosine kinase 2 inhibitor, TYK2 inhibitor, clinical trial

Abstract

N/A

References

1. SOTYKTU™ (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.

2. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

3. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

4. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.

5. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, September 29–October 2, 2021. Late breaker.

6. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, September 29–October 2, 2021.

7. Warren RB, et al. Presented at the EADV Spring Symposium; May 12–14, 2022.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>